Adavosertib

Zentalis Pharmaceuticals Announces FDA Clearance of the IND for Its Third Oncology Drug Candidate, ZN-c3, a WEE1 Inhibitor, and the Dosing of the First Patient in a Phase 1/2 Clinical Trial

Retrieved on: 
수요일, 12월 18, 2019
Research, FDA, Clinical trials, Biotechnology, Health, General Health, Other Science, Science, Oncology, Branches of biology, Cell Cycle, Biology, Cell biology, Wee1, PARP inhibitor, Cell cycle checkpoint, DNA replication, G2-M DNA damage checkpoint, Adavosertib

The Company is developing ZN-c3, an oral small molecule DNA Damage Response (DDR) drug candidate targeting WEE1 in cancer settings.

Key Points: 
  • The Company is developing ZN-c3, an oral small molecule DNA Damage Response (DDR) drug candidate targeting WEE1 in cancer settings.
  • WEE1 is a protein tyrosine kinase that regulates the cell cycle by serving as a checkpoint preventing DNA replication in the presence of DNA damage.
  • We believe these characteristics will provide for a differentiated drug product to help fight cancer, if ZN-c3 is approved.
  • The Company is evaluating the potential of ZN-c3 in a Phase 1/2 clinical trial as monotherapy and in combination with an FDA-approved PARP inhibitor.